Back to top
more

Fate Therapeutics (FATE)

(Delayed Data from NSDQ)

$4.15 USD

4.15
1,589,477

-0.09 (-2.12%)

Updated May 16, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for FATE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Fate Therapeutics, Inc. [FATE]

Reports for Purchase

Showing records 381 - 400 ( 426 total )

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 381

07/21/2015

Industry Report

Pages: 12

T-Cell Therapy Update: Companies Look Ahead to New Generation of TCell Therapies with Technology Enhancement Deals

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 382

07/21/2015

Industry Report

Pages: 12

T-Cell Therapy Update: Companies Look Ahead to New Generation of TCell Therapies with Technology Enhancement Deals

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 383

05/11/2015

Company Report

Pages: 11

1Q15 Update-Peek at PUMA Portends PROHEMA Potency; Raising PT

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: BENJAMIN R

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 384

05/07/2015

Company Report

Pages: 5

Q1:15 EPS; Key Data Readouts on Track for 2H:15, Building a Diverse Pipeline

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 385

05/06/2015

Company Report

Pages: 6

Collaboration with Juno Strong Validation of Fate''s Platform; Updated PUMA study Results

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 386

05/06/2015

Daily Note

Pages: 3

Positive PUMA Interim Readout and Steering the Fate of Adoptive T-Cell Therapies

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: BENJAMIN R

Price: 10.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 387

03/13/2015

Company Report

Pages: 5

Q4:14 EPS: Pivotal Year of Data Readouts Ahead for FATE, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 388

03/13/2015

Company Report

Pages: 11

4Q14 Update-Multiple Trials Fated for 2015 Readout

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: BENJAMIN R

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 389

03/06/2015

Industry Report

Pages: 6

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 390

03/06/2015

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events from the Week of March 9th

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 391

12/19/2014

Company Report

Pages: 3

PUMA Clears Second Independent Review

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: BENJAMIN R

Price: 10.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 392

12/18/2014

Daily Note

Pages: 4

ProHema Passes Second Interim Review in PUMA, Awaiting Final Data in Mid-15, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 393

12/14/2014

Industry Report

Pages: 5

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 394

12/12/2014

Industry Report

Pages: 5

LIFE SCIENCES AND HEALTH CARE-The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec 15

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 395

12/10/2014

Industry Report

Pages: 7

Biotechnology/Biopharmaceuticals/BioDefense-Recap of American Society for Hematology Meeting (ASH) 2014 Presentations

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 396

12/08/2014

Industry Report

Pages: 19

ASH 2014 Highlights From Days 1-2-More than CARs and Checkpoints

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: BENJAMIN R

Price: 50.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 397

11/17/2014

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov 17

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 398

11/11/2014

Company Report

Pages: 6

Q3:14, Data-Rich 2015, Exciting Preclinical Data for ProHema in Peripheral Blood to be Presented at ASH, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 399

11/07/2014

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov 10

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 400

10/12/2014

Daily Note

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 13

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party